Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Calcitonin-Salmon (Miacalcin) vs Lanreotide (Somatuline)
An educational, source-based comparison of Calcitonin-Salmon (Miacalcin) and Lanreotide (Somatuline) — how each peptide works, what it's researched for, and what to know before going deeper.
32-amino-acid peptide for osteoporosis and hypercalcemia.
Synthetic salmon calcitonin inhibits osteoclast-mediated bone resorption and promotes renal calcium excretion. Available as nasal spray or injection.
- Postmenopausal osteoporosis (>5 yrs postmenopause)
- Paget's disease
- Hypercalcemia
- • FDA-approved.
- • FDA cautions about possible malignancy signal with long-term use.
Long-acting somatostatin analog for acromegaly and NETs.
Cyclic octapeptide somatostatin analog with high affinity for SSTR2 and SSTR5. Suppresses GH secretion and slows progression of gastroenteropancreatic neuroendocrine tumors.
- Acromegaly
- Gastroenteropancreatic NETs
- Carcinoid syndrome
- • FDA-approved.
- • Monitor gallbladder, glucose, and thyroid function.
Calcitonin-Salmon (Miacalcin) vs Lanreotide (Somatuline) — Key differences
- Class: Calcitonin-Salmon (Miacalcin) is classified as Calcitonin · Bone Resorption, while Lanreotide (Somatuline) is Somatostatin Analog · Oncology.
- Primary research focus: Calcitonin-Salmon (Miacalcin) — postmenopausal osteoporosis (>5 yrs postmenopause); Lanreotide (Somatuline) — acromegaly.
- Tag: FDA-Approved · Bone vs FDA-Approved · Endocrine.